Share This Article:

Virological profile of hepatitis B infection in Black African HBsAg chronic carriers

Abstract Full-Text HTML Download Download as PDF (Size:134KB) PP. 113-118
DOI: 10.4236/ojgas.2013.32019    3,344 Downloads   5,691 Views   Citations

ABSTRACT

Aims: 1) Describe virological profile of patients followed-up for chronic Hepatitis B virus (HBV); 2) Search for a correlation between cirrhosis and virological profile of patients. Patients and Methods: Retrospective study about 75 HBsAg positive patients followed-up for at least one year in two medical structures of Abidjan. Studied parameters: clinical signs, biological check-up (serum transaminases every 3 months for at least one year, platelets count and prothrombin rate), abdominal echography, virological check-up (HBsAg, HBeAg, anti-HBe, total anti-HBc, anti-VHC and anti- HIV Ab, HBV DNA biannual quantification during at least one year). Histological or biochemical evaluation of hepatic activity and fibrosis were realized in case of transaminases elevation or HBV DNA > 2000 IU/ml. Results: The mean age of our 75 patients (54 men) was 42.1 ± 11.54 years. HBV was fortuitously discovered in most of our patients (74.7% of the cases). The HBV inactive chronic carriage was 50.7%; HBeAg-positive and HBeAg-negative chronic hepatitis represented respectively 9.3% and 40% of the cases. Mean B viral load was 327.5 IU/ml in HBV inactive chronic carriers, 44,047,663 IU/ml in HBeAg-positive chronic HBV and 20,231,822 IU/ml in HBeAg-negative chronic HBV. Cirrhosis prevalence was significantly high- er in positive or negative HBeAg chronic HBV than in HBV inactive chronic carriers (32.4% vs. 5.3%, p = 0.008; OR = 8.6). Conclusion: Our patients’ virological profile was dominated by HBeAg-negative chronic HBV and HBV inactive chronic carriage. The risk of having cirrhosis was multiplied by 8.6 in case of active chronic hepatitis compared with HBV inactive chronic carriage.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Attia, K. , Doffou, S. , Kissi, Y. , Bangoura, D. , Pianiza, S. , Mahassadi, K. , Bathaix, F. , Sayegh, M. and N’dri-Yoman, T. (2013) Virological profile of hepatitis B infection in Black African HBsAg chronic carriers. Open Journal of Gastroenterology, 3, 113-118. doi: 10.4236/ojgas.2013.32019.

References

[1] Wright, T.L. and Lau, J.Y.N. (1993) Clinical aspects of hepatitis B virus infection. Lancet, 342, 1340-1344. doi:10.1016/0140-6736(93)92250-W
[2] Murray, C.J. and Lopez, A.D. (1997) Mortality by cause for eight regions of the world: Global burden of disease study. Lancet, 349, 1269-1276. doi:10.1016/S0140-6736(96)07493-4
[3] Lai, C.L., Ratziu, V., Yeun, M.F. and Poynard, T. (2003) Viral hepatitis B. Lancet, 362, 2089-2094. doi:10.1016/S0140-6736(03)15108-2
[4] Goldstein, S.T., Zhou, F., Hadler, S.C., et al. (2005) A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology, 34, 1329-1339. doi:10.1093/ije/dyi206
[5] Trabut, J.B. (2009) The METAVIR scoring system. Hepato-Gastro, 16, 219-220.
[6] Florent, C., Meary, N., Abdini, E. and Mostefa-Kara, N. (1995) The natural history of oesophageal varices. Acta Endoscopica, 25, 319-326. doi:10.1007/BF02963250
[7] Rapicetta, M., Stroffolini, T., Ngatchu, T., et al. (1991) Ageand sex related study of HBV-DNA in HBs Ag asymptomatic children from an endemic area (Cameroon). Annals of Tropical Paediatrics, 11, 325-329.
[8] Abiodun, P.O., Olomu, A., Okolo, S.N., et al. (1994) The prevalence of hepatitis Be antigen and anti-HBE in adults in Benin City. West African Journal of Medicine, 13, 171-174.
[9] Harry, T.O., Bajani, M.D. and Moses, A.E. (1994) Hepatitis B virus infection among blood donors and pregnant women in Maiduguri, Nigeria. East African Medical Journal, 71, 596-597.
[10] Pawlotsky, J.M., Belec, L., Gresenguet, G., et al. (1995) High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. Journal of Medical Virology, 46, 269-272. doi:10.1002/jmv.1890460318
[11] Tswana, S., Chetsanga, C., Nystrom, L., et al. (1996) A sero-epidemiological cross-sectional study of hepatitis B virus in Zimbabwe. South African Medical Journal, 86, 72-75.
[12] Abebe, A., Nokes, D.J., Dejene, A., et al. (2003) Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: Transmission patterns and vaccine control. Epidemiology & Infection, 131, 757-770. doi:10.1017/S0950268803008574
[13] Otegbayo, J.A., Fasola, F.A. and Abja, A. (2003) Prevalence of hepatitis B surface and e antigens, risk factors for viral acquisition and serum transaminase among blood donors in Ibadan, Nigeria. Tropical Gastroenterology, 24, 196-197.
[14] Fujiwara, K., Tanaka, Y., Orito, E., et al. (2005) Distribution of HBV genotypes among HBV carriers in Benin: phylogenetic analysis and virological characteristics of HBV genotype E. World Journal of Gastroenterology, 11, 6410-6415.
[15] Hadziyannis, S.J. and Vassilopoulos, D. (2001) Hepatitis B e anti-gennegative chronic hepatitis B. Hepatology, 34, 617-624. doi:10.1053/jhep.2001.27834
[16] Funk, M.L., Rosenberg, D.M. and Lok, A.S. (2002) World-wide epidemiology of HBe Ag negative chronic hepatitis B and associated precore and core promoter variants. Journal of Viral Hepatitis, 9, 52-61. doi:10.1046/j.1365-2893.2002.00304.x
[17] Zarski, J.P., Marcellin, P., Leroy, V., et al. (2005) Quelles différences existe-t-il entre un porteur chronique inactif et un malade atteint d’hépatite virale chronique B antigène HBe négatif? Gastroentérologie Clinique et Biologique, 29, A177.
[18] Hadziyannis, S.J. and Papatheodoridis, G.V. (2006) Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment. Seminars in Liver Disease, 26, 130-141. doi:10.1055/s-2006-939751
[19] Fattovich, G., Bortolotti, F. and Donato, F. (2008) Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology, 48, 335-352. doi:10.1016/j.jhep.2007.11.011
[20] Xu, Z.Y., Liu, C.B., Francis, D.P., et al. (1985) Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: Preliminary report of a randomized double-blind placebo-controlled and comparative trial. Pediatrics, 76, 713-718.
[21] Lo, K.J., Tsai, Y.T., Lee, S.D., et al. (1985) Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology, 32, 65-68.
[22] Merican, I., Guan, R., Amarapuka, D., et al. (2000) Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology, 15, 1356-1361. doi:10.1046/j.1440-1746.2000.0150121356.x
[23] Chen, H.L., Lin, L.H., Hu, F.C., et al. (2012) Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology, 142, 773-781. doi:10.1053/j.gastro.2011.12.035
[24] Hoffmann, C.J. and Thio, C.L. (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infectious Diseases, 7, 402-409. doi:10.1016/S1473-3099(07)70135-4
[25] Hadziyannis, S.J. (2011) Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries. Journal of Hepatology, 55, 183-191. doi:10.1016/j.jhep.2010.12.030
[26] Kramvis, A. and Kew, M.C. (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatology Research, 37, S9S19. doi:10.1111/j.1872-034X.2007.00098.x
[27] Lohouès-Kouacou, M.J., Touré, M., Hillah, J., et al. (1998) Materno-fetal transmission of hepatitis B virus in Ivory Coast. Plea for mass vaccination. Sante, 8, 401-404.
[28] Candotti, D., Danso, K. and Allain, J.P. (2007) Maternofetal transmission of hepatitis B virus genotype E in Ghana, West Africa. Journal of General Virology, 88, 2686-2695. doi:10.1099/vir.0.83102-0
[29] Sangaré, L., Sombié, R., Combasséré, A.W., et al. (2009) Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso. Bulletin de la Société de Pathologie Exotique, 102, 226-229.
[30] Del Canho, R., Grosheide, P.M., Mazel, J.A., et al. (1997) Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: Protective efficacy and longterm immunogenicity. Vaccine, 15, 1624-1630. doi:10.1016/S0264-410X(97)00080-7
[31] Pan, C.Q., Duan, Z., Bhamidimarri, K.R., et al. (2012) An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clinical Gastroenterology and Hepatology, 10, 452-459. doi:10.1016/j.cgh.2011.10.041
[32] Zou, H., Chen, Y., Duan, Z., et al. (2012) Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. Journal of Viral Hepatitis, 19, e18-e25. doi:10.1111/j.1365-2893.2011.01492.x
[33] Pol, S. (2007) Epidemiology and natural history of HBV infection. Hepato-Gastro, 14, 6-15.
[34] Fattovich, G., Bortolotti, F. and Donato, F. (2008) Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Viral Hepatitis, 48, 335-352. doi:10.1016/j.jhep.2007.11.011
[35] Chu, C.M. and Liaw, Y.F. (2009) Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Journal of Viral Hepatitis, 104, 16931699. doi:10.1038/ajg.2009.187
[36] Lok, A.S. and McMahon, B.J. (2009) Chronic hepatitis B: Update 2009. American Association for the Study of Liver Diseases Practice Guidelines. Hepatology, 50, 661662. doi:10.1002/hep.23190
[37] Liaw, Y.F., Kao, J.H., Piratvisuth, T., et al. (2012) AsianPacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatology International, 6, 531-561. doi:10.1007/s12072-012-9365-4
[38] European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology, 57, 167-185.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.